The significant association between higher level of serum HMGB1 and longer PFS was also observed in patients with NSCLC expressing PD-L1 TPS ≥ 50% (median PFS, 12.4 months vs. 4.4 months, p = 0.03; Fig. 3e), but not in patients with NSCLC expressing PD-L1 TPS < 50% or unknown (median PFS, 2.8 months vs. 2.3 months, p = 0.46; Fig. 3f). The gene discussed is CD274; the disease is non-small cell lung carcinoma.